Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients

Bernard Ma?tre; Caroline Jannière-Nartey; Jehan Dupuis; Kamel Amraoui; Karim Belhadj

首页> 外文期刊>European respiratory review >Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients

【24h】

Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients

机译：来那度胺长期治疗对两名骨髓瘤患者的肺毒性

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European respiratory review 》 |2013年第127期| 共页
作者
Bernard Ma?tre; Caroline Jannière-Nartey; Jehan Dupuis; Kamel Amraoui; Karim Belhadj;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类呼吸系及胸部疾病 ;
关键词

相似文献

外文文献
中文文献
专利

1. Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents? [J] . Gassiot Susanna, Gonzalez Yolanda, Morgades Mireia, Clinical lymphoma, myeloma & leukemia . 2019 ,第9期

机译：对第一周期的回应是长期反应的主要预测因子，对即甘露二钒和地塞米松治疗复发和难治性多发性多发性骨髓瘤：我们可以备患者毒性和成本的额外药剂吗？
2. Elderly multiple myeloma (MM) patients, who are generally ineligible for transplantation, have high risks of death and treatment discontinuation, and require a regimen incorporating novel agents that balance safety, tolerability, and efficacy. We evaluated alternating bortezomib-dexamethasone and lenalidomide-dexamethasone treatments administered over a 63-day cycle in transplant-ineligible elderly patients with newly diagnosed MM. Subcutaneous bortezomib 1.3 mg/m2 was administered weekly on Days 1, 8, 15, and 22; oral lenalidomide 15 mg daily on Days 36-56; and oral dexamethasone 20 mg on Days 1, 8, 15, 22, 36, 43, 50, and 57 for 6 cycles. The primary endpoint was the overall response rate. [J] . Yokoyama Akihiro, Kada Akiko, Saito Akiko M., Acta medica Okayama . 2019 ,第6期

机译：通常不适合移植的老年多发性骨髓瘤（MM）患者具有很高的死亡和中止治疗的风险，因此需要一种方案，该方案应采用能够平衡安全性，耐受性和疗效的新型药物。我们评估了在不适合移植的老年初诊MM患者中，硼替佐米-地塞米松和来那度胺-地塞米松在63天周期内的交替治疗。在第1、8、15和22天每周一次皮下注射硼替佐米1.3 mg / m2;在第36-56天每天口服来那度胺15 mg;在第1、8、15、22、36、43、50和57天，口服地塞米松20 mg，共6个周期。主要终点是总体缓解率。
3. Immortal time bias in retrospective analysis: comment on ‘Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma’ [J] . P-Y Hsieh, C-J Liu, C-J Teng Blood cancer journal. . 2015 ,第2期

机译：回顾分析中不朽的时间偏差：评论“来那度胺和地塞米松长期治疗对复发/难治性多发性骨髓瘤患者的疗效和安全性”
4. PATIENT-SPECIFIC THREE-DIMENSIONAL COMPUTATIONAL HEART MODELING AND PRINTING TO ENHANCE CLINICAL UNDERSTANDINGS AND TREATMENT PLANNING: CONGENITAL RECURRENT PULMONARY ARTERY STENOSIS AND TRANSCATHETER PULMONARY VALVE REPLACEMENT [C] . Amanda C. Tenhoff, Varun Aggarwal, Rebecca Ameduri, Design of Medical Devices Conference . 2021

机译：患者特异性三维计算心脏建模和印刷，增强临床谅解和治疗计划：先天性复发性肺动脉狭窄和经导管肺瓣膜置换
5. Liposomal antimicrobial agent formulations for the treatment of pulmonary infection in cystic fibrosis patients. [D] . Halwani, Majed Abdulaziz. 2010

机译：脂质体抗微生物剂制剂，用于治疗囊性纤维化患者的肺部感染。
6. Immortal time bias in retrospective analysis: comment on ‘Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma [O] . P-Y Hsieh, C-J Liu, C-J Teng 2015

机译：回顾分析中不朽的时间偏差：评论来那度胺和地塞米松长期治疗对复发/难治性多发性骨髓瘤患者的疗效和安全性
7. Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients [O] . K. Amraoui, K. Belhadj, B. Maitre, 2013

机译：在两种骨髓瘤患者中长期治疗后长期治疗后的肺毒性

Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients

著录项

相似文献

相关主题

期刊订阅